Fig. 1 2D representation of the CD20 antigen (previously known as “B1”). Note that antibodies used in RIT bind to the extracellular domain. This figure was published in American Journal…
Fig. 1 Scheme of particle distribution in tissues. Shown are several electrons and an alpha particle. Clearly, total energy absorbed per unit mass, i.e., dose correlates with the number of particles…
Fig. 1 A schematic comparison of energy types for therapeutic radionuclides (Srivastava 2012) In general, all high-LET emitters are much more effective for small lesions and for micrometastatic disease. For example,…
Fig. 1 Publications describing rhenium-188 radiopharmaceutical development and clinical trials (data from MedLine) From a clinical perspective, radionuclide therapy has a high impact in the treatment of benign diseases, such as…
Global N = 206 Group under analysis All grades Grade 4 Radiation pneumonitis 206 treatments 1 (0.4 %) 0 GI ulcers 215 procedures 3 (1.4 %) 0 REILD (global) 206 treatments 24 (11 %)…
Type of disease Strategy Goal Single spots “rule of five” <5 cm diameter; <5 spots RFTA, (LITT), MW Complete destruction A0-ablation/curation Small hypervascularized lesion TAE with embozene; alternative: DC-Beads Complete destruction/curation Big…
Here D β is the beta dose in rad, C is the concentration of the nuclide in the tissue in microcuries per gram, E β is the mean energy emitted…
(1) (2)where:Ã is the integral activity of each source; S are Snyder factors from each source to target; A0 is the injected activity; τ (MIRD) is the residence time; ND…
where (1−νx e 1−(νx/c)) = 0 for x > c/ν, D(x) is the dose rate at distance x from the source, ν is the absorption coefficient, k is a normalisation constant, c is a…
Fig. 1 Radioactivity distribution within the patch (a). 166Ho-impregnated patch for skin cancer treatment. The size and shape can be easily adjusted according to those of cancers or precancerous lesions (b)….
